cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
3 own
6 watching
Current Price
$3.17
$-0.3
(-8.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
199.79M
52-Week High
52-Week High
11.31000
52-Week Low
52-Week Low
1.81000
Average Volume
Average Volume
0.63M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization199.79M
icon52-Week High11.31000
icon52-Week Low1.81000
iconAverage Volume0.63M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer s disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
TipRanks Financial Blog
1 year ago
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS Research Report), with a price t... In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS &#8211...
Zolmax
1 year ago
Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) and Elevation Oncology (NASDAQ:ELEV Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, ...
Globe Newswire
1 year ago
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing a novel ...
Zolmax
1 year ago
HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. ABOS has been the subject of a number of other research reports. ...
Globe Newswire
1 year ago
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease (AD), today announced Derrell ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$3.17
$-0.3
(-8.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00